VC
ACER

Vivo Capital’s Acer Therapeutics Inc ACER Stock Holding History

Vivo Capital’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-579,051
Closed -$14.1M – 51
2019
Q1 		$14.1M Hold
579,051
– – 1.4% 20
2018
Q4 		$11.7M Buy
579,051
+13,472
+2% +$310K 1.49% 20
2018
Q3 		$17.4M Buy
+565,579
New +$15.2M 1.76% 20

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vivo Capital's ACER Position: Q2 2019 in Review

Vivo Capital sold out of Acer Therapeutics Inc (ACER) in Q2 2019, closing a stake of 579,051 shares — an estimated $14.1M sold.

Vivo Capital first reported a position in ACER in Q3 2018 and held it in 3 quarters. The position peaked at $17.4M in Q3 2018. 37 funds tracked by Wall St. Rank hold ACER as of Q2 2019.

  • Vivo Capital reported no remaining Acer Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
  • Vivo Capital sold 579,051 Acer Therapeutics Inc shares in Q2 2019, an estimated $14.1M.
  • Vivo Capital first reported a position in Acer Therapeutics Inc in Q3 2018 and held it in 3 quarters.
  • Vivo Capital's Acer Therapeutics Inc position peaked at $17.4M in Q3 2018.
  • 37 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2019.

Based on Vivo Capital's 13F filing for Q2 2019, filed 13 Aug 2019.